GlassScriptPhysician profile
Steven M Gudis
NPI 1396719845
$1,731.75
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $405 · 2021: $495 · 2022: $251.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $233.43 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $189.11 | 2019-2022 | |
| Amgen INC. | $179.51 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $129.02 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.65 | 2021-2022 | |
| Lilly USA, LLC | $106.87 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $97.11 | 2019-2021 | |
| Akebia Therapeutics INC | $90.89 | 2019-2021 | |
| Pfizer INC. | $73.77 | 2019-2021 | |
| Vifor Pharma, INC. | $59.00 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $56.66 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $43.33 | 2019-2021 | |
| Allergan, INC. | $41.08 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.40 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $36.32 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $29.22 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $26.94 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $26.39 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.22 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $25.85 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.66 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2019 | |
| Horizon Therapeutics Plc | $13.56 | 2021 | |
| Sanofi Pasteur INC. | $12.55 | 2019 | |
| Kaleo, INC. | $12.31 | 2021 | |
| Aurinia Pharma U.S., INC. | $11.62 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gudis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.